New York, September 05, 2014 -- Moody's Investors Service applied its Ba3 rating to U.S. Renal Care, Inc.'s ("U.S. Renal") proposed offering of a $75 million first lien term loan add-on due 2019. Moody's understands that the proceeds, along with $25 million of cash will be used to fund two acquisitions. Given that Moody's expects the offering, in combination with the acquisitions, to be slightly deleveraging, the existing ratings of the company remain unchanged. These include the B2 Corporate Family Rating and B2-PD Probability of Default Rating. The rating outlook is negative.

Vollständigen Artikel bei Moodys lesen